🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 05/12/2006 | 44,50 | 44,75 | 44,32 | 44,54 | +0,79% | 0,97% | 1.765.500 |
| 04/12/2006 | 44,40 | 44,79 | 43,39 | 44,19 | +0,11% | 3,15% | 1.504.200 |
| 01/12/2006 | 44,01 | 44,62 | 43,40 | 44,14 | -0,36% | 2,77% | 1.131.900 |
| 30/11/2006 | 44,82 | 45,38 | 43,95 | 44,30 | -1,31% | 3,19% | 1.513.100 |
| 29/11/2006 | 44,21 | 44,90 | 43,63 | 44,89 | +2,44% | 2,87% | 1.757.800 |
| 28/11/2006 | 42,83 | 44,03 | 42,61 | 43,82 | +2,03% | 3,32% | 2.883.100 |
| 27/11/2006 | 43,28 | 44,62 | 42,72 | 42,95 | -4,34% | 4,39% | 1.685.800 |
| 24/11/2006 | 44,63 | 44,99 | 44,17 | 44,90 | +0,00% | 1,84% | 273.800 |
| 22/11/2006 | 44,19 | 45,01 | 44,00 | 44,90 | +1,77% | 2,29% | 770.600 |
| 21/11/2006 | 44,50 | 45,20 | 43,72 | 44,12 | -2,22% | 3,33% | 1.050.300 |
| 20/11/2006 | 44,31 | 45,34 | 44,17 | 45,12 | +1,39% | 2,64% | 1.375.200 |
| 17/11/2006 | 44,76 | 44,80 | 44,04 | 44,50 | -0,36% | 1,70% | 999.800 |
| 16/11/2006 | 44,74 | 45,00 | 44,13 | 44,66 | +1,59% | 1,94% | 1.631.500 |
| 15/11/2006 | 42,89 | 44,26 | 42,83 | 43,96 | +2,97% | 3,33% | 1.780.200 |
| 14/11/2006 | 42,42 | 43,00 | 41,84 | 42,69 | +0,49% | 2,73% | 1.258.600 |
| 13/11/2006 | 42,00 | 43,45 | 41,88 | 42,48 | +0,85% | 3,74% | 1.267.700 |
| 10/11/2006 | 41,06 | 42,19 | 40,32 | 42,12 | +2,38% | 4,55% | 1.630.000 |
| 09/11/2006 | 42,14 | 42,42 | 40,82 | 41,14 | -1,91% | 3,80% | 1.159.800 |
| 08/11/2006 | 41,50 | 42,92 | 40,93 | 41,94 | -0,02% | 4,80% | 1.426.800 |
| 07/11/2006 | 40,37 | 43,00 | 40,37 | 41,95 | +4,17% | 6,51% | 3.103.500 |
| 06/11/2006 | 39,71 | 40,75 | 39,44 | 40,27 | +1,79% | 3,30% | 1.163.900 |
| 03/11/2006 | 39,81 | 40,09 | 38,88 | 39,56 | -0,25% | 3,04% | 924.300 |
| 02/11/2006 | 39,58 | 39,82 | 38,83 | 39,66 | -0,30% | 2,50% | 1.043.000 |
| 01/11/2006 | 40,66 | 41,01 | 39,75 | 39,78 | -2,02% | 3,10% | 1.270.400 |
| 31/10/2006 | 39,81 | 40,67 | 39,78 | 40,60 | +1,70% | 2,24% | 1.744.300 |
| 30/10/2006 | 40,19 | 40,44 | 39,25 | 39,92 | -1,82% | 2,96% | 2.722.900 |
| 27/10/2006 | 40,00 | 41,56 | 39,36 | 40,66 | +17,62% | 5,50% | 14.520.000 |
| 26/10/2006 | 33,79 | 34,81 | 33,65 | 34,57 | +2,80% | 3,43% | 1.500.800 |
| 25/10/2006 | 33,38 | 33,75 | 33,16 | 33,63 | +0,93% | 1,77% | 875.100 |
| 24/10/2006 | 33,49 | 33,87 | 32,50 | 33,32 | -1,10% | 4,09% | 1.558.500 |